GlassScriptPhysician profile
Royal M Becker
NPI 1588637698
$848.27
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $283 · 2021: $173 · 2022: $14.17.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $214.22 | 2019-2021 | |
| Pfizer INC. | $192.24 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $145.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $74.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $40.57 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $38.37 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $37.46 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $32.43 | 2019 | |
| Melinta Therapeutics, LLC | $28.78 | 2019-2020 | |
| Shire North American Group INC | $17.59 | 2019 | |
| Vifor Pharma, INC. | $13.34 | 2021 | |
| Smith+Nephew, INC. | $13.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Royal Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.